Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
Investment Advisor May 2010 Ron Pechtimaldjian	For Small Businesses, Confusion and Added Costs Of all the debate about healthcare reform, the effect on small businesses seems to have generated the most confusion.
The Motley Fool April 4, 2011 Selena Maranjian	This Expense Could Wipe You Out You probably already realize that a significant amount of your spending in retirement will go toward health care. But you may still be surprised when you see the actual average price tag.
Financial Planning May 1, 2010 Rick S. Kahler	Planning for Reform It will be important to pay attention in coming months, so you can plan for the impact health care reform is likely to have on your finances, your career and your clients.
The Motley Fool August 4, 2009 Selena Maranjian	A Tax Hike for Dividends and Capital Gains? The administration has proposed capping dividend and capital gains taxes at 20%, even for high-income taxpayers. That's a tax hike, but not as big an increase as some fear.
Registered Rep. April 17, 2013 Kevin McKinley	Sheltering Clients From the Taxman Several investment strategies can protect high-income clients from new taxes and higher tax rates.
Financial Planning July 1, 2010 Ed Slott	Strange Bedfellows It probably didn't cross your mind that the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act, both signed into law in March, might affect IRA planning.
Financial Planning February 1, 2005 Neil A. O'Hara	The Harvest to Come Pharmaceutical stocks may be down, but they're hardly out. For planners and clients who can tolerate the risk of concentration, a selective allocation to the healthcare industry today may represent the ability to buy growth at a value price.
Pharmaceutical Executive April 1, 2011	Revisiting Reform Courts, Congress review policies and programs shaping drug costs and access.
BusinessWeek October 22, 2009 Sasseen & Arnst	Who Picks Up the Tab for Health Reform Insurers and taxpayers are likely to pay big chunks of the $900 billion bill to overhaul the nation's health-care system. Doctors will feel the least pain.
Financial Planning April 1, 2006 Donald Jay Korn	Rx for Investing Healthcare stocks may cure investors' ills over the long term, but the current prognosis is less clear. For clients in diversified funds, planners should decide whether additional healthcare exposure is justified, through individual stocks or specialized funds.
Searcher October 2010 Stephanie C. Ardito	The Medical Digital: U.S. Healthcare Reform: A Follow-Up For those interested in serious, scholarly research regarding the historical progress of U.S. healthcare reform, this column and my prior column might be a good pairing for neutral sources.
Financial Advisor October 2004 Eric L. Reiner	Year-End Tax Strategies, Edition 2004 AMT (alternative minimum tax) and historically low tax rates demand advisors' attention.
Investment Advisor August 2009 Melanie Waddell	Healthcare Reform Steamroller Advances House and Senate committees offer health reform bills. Both the House and Senate legislation would likely raise taxes for many.
Pharmaceutical Executive February 1, 2009 Jill Wechsler	Securing Savings A close look at the healthcare industry will separate real cost-cutting measures from money-saving myths.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Investment Advisor October 2009	Asset Allocation This month's asset allocation numbers.
Registered Rep. March 1, 2005 David A. Twibell	What Ails You? Investors who are wary of big pharma investments have good reasons to be. But this does not mean that the sector is to be avoided at all costs. Indeed, for savvy, well-informed investors, now might be a good time to jump in.
Pharmaceutical Executive March 1, 2013 Sillup et al.	Back in the News Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues.
Financial Advisor June 2010 Eric L. Reiner	Coming Down The Pike Health-care reform gave birth to new income tax laws that are crying for attention.
Investment Advisor September 2009 Melanie Waddell	Danger & Opportunity: Stitching Together Healthcare Reform The healthcare debate moved outside the beltway in August, as members of Congress headed back home to face constituents bent on voicing their opinions on healthcare reform during townhall meetings.
Investment Advisor May 2010 Melanie Waddell	Healthcare Reform and You The new healthcare law brings changes in taxes, investing, annuities, and health savings accounts.
Pharmaceutical Executive February 1, 2007 Humphrey Taylor	Opinion: Myth vs. Reality The debate about reform of the American healthcare system has been ideologically driven rather than evidence-based. Here, we separate myth from reality.
Financial Planning October 1, 2005 John Nersesian	The Stealth Tax Millions of middle-class clients are falling into the alternative minimum tax (AMT) trap. Here's how financial advisers can help lower clients' total tax bills.
Financial Planning February 1, 2013 Ilana Polyak	15 Tax Moves for Right Now The eleventh-hour tax deal reached in Washington will require some new strategies for advisors and their clients.
Financial Planning July 1, 2006 Robert M. Hayes	Preserve Medicare Medicare is a roadmap for the future healthcare of America. It should be fine-tuned and improved, not undermined and privatized as the Washington power brokers are now attempting to do.
Pharmaceutical Executive October 1, 2012 Nicolas Pechet	Your Local Competitor: A Threat in Emerging Markets? Pharmaceutical companies looking to wrest market share in high growth markets of tomorrow must overcome challenges from a new crop of national champions.
Nursing Management April 2011 Deborah E. Trautman	Healthcare Reform: 1 Year Later A year after the Patient Protection and Affordable Care Act was signed into law, the nation remains divided.
Financial Planning April 1, 2011 Donald Jay Korn	Front and Center With baby boomer clients entering the age of Medicare, it will become increasingly important for planners to keep up with the inevitable new wrinkles.
The Motley Fool January 28, 2010 Brian Orelli	Health-Care Reform Is Dead. Probably. Breaking up the bill doesn't seem like the answer. What do insurers and pharmaceutical companies have to say?
Pharmaceutical Executive March 1, 2012 Sillup & Porth	Pharma & The Press Our eighth annual press audit finds the industry out of the crosshairs for now.
The Motley Fool January 13, 2010 Dan Caplinger	This Could Cause the Next Crash Higher taxes will transform the investment world.
BusinessWeek February 16, 2004 Howard Gleckman	The Stealth Tax The AMT now sideswipes 3 million taxpayers. Think you're not one of them? Better cross your fingers.
Investment Advisor October 2005 Kathleen M. McBride	Relief Pitcher How do you spell relief from the alternative minimum tax? Try the Fidelity Tax-Free Bond Fund, a fund that provides strong returns largely free of the AMT heartburn.
Pharmaceutical Executive May 1, 2005 Robert Ullmann	Back Page: Unhealthy Justice More than any other healthcare law, the Medicare/Medicaid exclusion statute has distorted our criminal justice system with government fraud investigations. This well-intentioned but misguided law should be repealed.
Investment Advisor January 2009 Kara P. Stapleton	Asset Allocation The latest market numbers and asset allocations from our panel of experts.
Entrepreneur September 2006 Carol Tice	Steer Clear How you can avoid paying the Alternative Minimum Tax now and later.
Pharmaceutical Executive November 1, 2008 Patrick Clinton	Pharm Exec Q&A: Tommy Thompson The former health secretary offers a reality check on healthcare reform and what to expect in '09.
Pharmaceutical Executive July 30, 2007 Peter Pitts	Opinion: Fewer Cents, More Sense Our healthcare system may be broken, but playing the blame game is not going to fix it. Remember that disease - not Big Pharma - is the enemy.
Financial Planning April 1, 2010 Rick Kahler	Healthcare on the Critical List Even if Congress does enact a new law, it seems that the same old problems will remain, at least for the next few years. So let's take a careful look at what's at stake.
The Motley Fool May 20, 2011 Arlene Weintrab.	Miller Tabak Fund Manager Says Investors Are Ignoring the Upsides in Healthcare This manager says investors in 2013 are going to look back and wish they had invested more in healthcare funds today.
Pharmaceutical Executive October 1, 2005 Philip A. George	Backpage: Under Surveillance Doctors and consumers don't doubt that pharma benefits society. But in the eyes of the public, industry efforts to monitor postmarket safety come up short.
Investment Advisor July 2009 Melanie Waddell	The Great Health Reform Debate President Barack Obama has set an ambitious deadline of October to achieve comprehensive healthcare reform.
Registered Rep. October 1, 2004 Stan Luxenberg	Ticking Tax Bomb Alternative Minimum Tax (AMT) surprises could become increasingly common for shareholders of municipal bond funds. Advisors must now decide whether to buy funds with private bonds.
Financial Planning March 1, 2005 Donald Jay Korn	The Devil's Alternative Savvy planning can shave a few points from the alternative minimum tax, a numbers game where the house always wins.
The Motley Fool April 6, 2009 Michael P. Cecil	Investing in Pharma? Remember Rule No. 1 Health care reform is likely this year. How will that affect your pharma investments?
Pharmaceutical Executive February 1, 2011 Jon Zifferblat	China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country
Pharmaceutical Executive December 1, 2008 Jill Wechsler	Challenge and Challenges Expanded healthcare coverage also fits the goals of pharma manufacturers.
Pharmaceutical Executive May 1, 2007 Diane West	Spend Trends 2007: Hang 10 Direct-to-Consumer Advertising Hits Its First Decade: Dr. Dot-Com... Digital Detailing... etc.
Pharmaceutical Executive April 1, 2009 Jill Wechsler	Kickoff for Reform In addition to overhauling healthcare, Congress is weighing proposals for updating FDA policies and expanding access to drugs.